Hemostatic parameters in sepsis patients treated with anti-TNFα-monoclonal antibodies

Shock

Volumn 6, Issue 4, 1996, Pages 233-237

  Salat, Christoph ^a,f   Boekstegers, Peter ^a   Holler, Ernst ^a,b   Werdan, Karl ^c   Reinhardt, Brigitte ^a   Fateh Moghadam, Susanne ^d   Pihusch, Rudolf ^a   Kaul, Martin ^e   Beinert, Thomas ^a   Hiller, Erhardt ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e Knoll AG   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; FIBRIN DEGRADATION PRODUCT; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM; FIBRINOLYSIS; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SEPSIS; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SEPSIS; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0030253611     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199610000-00001     Document Type: Article

References (35)

1. Hoffmann WD: Anti-endotoxin therapies in septic shock. In Natanson C: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:772-775, 1994.
2. Tracey KJ, Lowry SF, Fahey TJ, et al: Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164:415-422, 1987.
3. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
4. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823-832, 1989.
5. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 101:816-823, 1992.
6. Hoek J, Sturk A, ten Cate JW, Lamping RJ, Berends F, Borm JJ: Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 34:2058-2062, 1988.
7. Thijs LG, de Boer JP, de Groot MCM, Hack CE: Coagulation disorders in septic shock. Intensive Care Med 19:S8-S15:1993.
8. Van der Poll T, Büller HR, ten Cate H, et al: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622-1627, 1990.
9. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD: Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanisms of humans. Blood 74:165-172, 1989.
10. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxinemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathway. Blood 76:2520-2526, 1990.
11. Van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729-732, 1991.
12. Van der Poll T, Levi M, van Deventer SJH: Tumor necrosis factor and the disbalance between coagulant and anticoagulant mechanisms in septicemia. In Vincent JL (ed): Update in Intensive Care and Emergency Medicine 14. Berlin: Springer-Verlag, 1991, pp 269-273.
13. 100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 30:279-292, 1990.
14. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664, 1987.
15. Pilz G, Gurniak T, Bujdoso O, Werdan K: A basic program for calculation of apache II and elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 21:143-159, 1991.
16. Elebute EA, Stoner HB: The grading of sepsis. Br J Surg 70:29-31, 1983.
17. Knaus WA, Draper EA, Wagner DP, Zimmermann JE: APACHE II: A severity of disease classification system. Crit Care Med 13:818-829, 1985.
18. 2 after administration of anti-TNFα-antibody in patients with severe sepsis: Comparison to interleukin-6 serum levels, apache II, and elebute scores. Shock 1:246-253, 1994.
19. 2 fragment of an anti-tumor-necrosis factor α monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock 1:237-245, 1994.
20. Holler E, Kolb HJ, Mittermüller J, et al: Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF α) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 86:890-899, 1995
21. Damas P, Reuter A, Gysen P, Demonty H, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975-978, 1989.
22. Offner F, Philippe J, Vogelaers D, et al: Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 116:100-105, 1990.
23. Marks JD, Marks CB, Luce JM, Montgomery B, Turner J, Metz CA, Murray JF: Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 141:94-97, 1990.
24. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740-745, 1986.
25. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA: Monoclonal antibody to tumor necrosis factor a prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120:574-588, 1992.
26. van der Poll T, Levi M, van Deventer SJH, et al: Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83: 446-451, 1994.
27. Van Hinsbergh VW, Kooistra T, Van Den Berg EA, Princen HM, Fiers W, Emeis JJ: Tumor necrosis factor increases the production of plasminogen acctivator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467-1473, 1988.
28. Medcalf RL, Kruithof EKO, Schleuning WD: Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin responsive genes. J Exp Med 168:751-759, 1988.
29. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165-1172, 1989.
30. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO: Plasminogen activator inhibitor 1: A prognostic marker in septic shock. Thromb Haemostas 61:459-462, 1989.
31. Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D: Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemostas 65:291-295, 1991.
32. Paleolog EM, Crossman DC, Mc Vey JH, Pearson JD: Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 75:688-695, 1990.
33. Möller A, Emling F, Blohm D: Monoclonal antibodies to human tumor necrosis factor α: In vitro and in vivo application. Cytokine 2:162-169, 1990.
34. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor α in experimental gramnegative shock. J Infect Dis 162:421-427, 1990.
35. Reinhardt K, Wiegand-Löhnert C, Grimminger F, et al: Treatment of severe sepsis with anti-TNF monoclonal antibody MAK 195F: Dose dependent reduction of mortality in patients with elevated IL-6 levels (abstr). Clin Intens Care 6(Suppl):82, 1995.